Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor Data

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a small-molecule, multi-target tyrosine kinase inhibitor supplied by APExBIO, targeting VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM), and FGFR1 (IC₅₀ = 11.7 ± 4.1 nM) (Gene, 2018). It effectively inhibits endothelial cell migration and capillary-like tube formation in vitro, suppressing ERK pathway activation without significant cytotoxicity up to 1 μM. Pharmacokinetic studies show high bioavailability, plasma protein binding, and blood-brain barrier penetration. Compared to sunitinib, sorafenib, and nintedanib, Anlotinib exhibits superior anti-angiogenic performance and is suitable for advanced functional assays in cancer research (APExBIO product information).

Biological Rationale

Angiogenesis, the process of new blood vessel formation, is critical for tumor growth and metastasis (Gene, 2018). Tumors secrete pro-angiogenic factors such as VEGF, PDGF-BB, and FGF-2 to induce migration and tube formation in endothelial cells. The inhibition of these pathways is a proven strategy in cancer therapy. Multi-target tyrosine kinase inhibitors (TKIs), like anlotinib hydrochloride, provide a means to block multiple signaling axes essential for angiogenesis and tumor proliferation. Recent research demonstrates that targeting VEGFR2, PDGFRβ, and FGFR1 can more effectively suppress tumor vascularization than single-kinase inhibition (Gene, 2018).

Mechanism of Action of Anlotinib hydrochloride

Anlotinib hydrochloride is a selective inhibitor of VEGFR2, PDGFRβ, and FGFR1 tyrosine kinases. By binding to these receptors, it prevents their phosphorylation and subsequent activation of downstream pathways, especially the ERK signaling cascade. In vitro, anlotinib significantly suppresses VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and capillary tube formation (Gene, 2018). This blockade results in robust inhibition of angiogenesis and tumor cell proliferation. Unlike many other TKIs, anlotinib shows no significant cytotoxicity at concentrations up to 1 μM, preserving cell viability during functional assays (APExBIO).

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2 kinase activity with an IC₅₀ of 5.6 ± 1.2 nM in cell-free assays (Gene, 2018).
• PDGFRβ and FGFR1 activity are inhibited with IC₅₀ values of 8.7 ± 3.4 nM and 11.7 ± 4.1 nM, respectively (Gene, 2018).
• In EA.hy 926 endothelial cells, anlotinib suppresses VEGF/PDGF-BB/FGF-2-induced migration and tube formation in a concentration-dependent manner (Gene, 2018).
• Shows superior anti-angiogenic activity compared to sunitinib, sorafenib, and nintedanib in both in vitro and in vivo models (Gene, 2018).
• Pharmacokinetics: Oral bioavailability ranges 28–58% in rats and 41–77% in dogs; high plasma protein binding (93–97%) and a terminal half-life of 5.1 ± 1.6 h in rats, 22.8 ± 11.0 h in dogs (APExBIO).
• Crosses the blood-brain barrier and distributes extensively in tissues (APExBIO).
• Low cytotoxicity at concentrations up to 1 μM in functional assays (APExBIO).
• Metabolized mainly by CYP3A, yielding hydroxylated and dealkylated products (APExBIO).

For a detailed comparison of anti-angiogenic selectivity and assay design, see this internal review, which this article updates by reporting newly validated IC₅₀ values and in vivo distribution data.

For advanced workflow recommendations, this guide covers troubleshooting strategies; the present article clarifies mechanistic selectivity and pharmacokinetic parameters.

Mechanistic insights are also expanded in this analysis, but this dossier uniquely details comparative efficacy benchmarks and safety margins.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is used in research settings to dissect angiogenesis mechanisms, validate anti-angiogenic targets, and benchmark therapeutic TKIs in cancer models. Its low cytotoxicity at research concentrations makes it ideal for functional endothelial cell assays and high-content screening. The compound is not indicated for clinical use or as a therapeutic agent in humans outside controlled trials.

Common Pitfalls or Misconceptions

• Not a clinical drug: Anlotinib hydrochloride from APExBIO is for research use only; it is not formulated or approved for therapeutic administration.
• Assay context dependency: Potency and selectivity may differ in primary versus immortalized endothelial cells or under serum-rich versus serum-free conditions.
• Not a pan-kinase inhibitor: Selectivity is limited to VEGFR2, PDGFRβ, and FGFR1; activity against unrelated kinases is not established.
• No proven effect on non-angiogenic processes: Current evidence does not support use in models where angiogenesis is not a primary driver.
• Potential for CYP-mediated interactions: Although in vitro CYP3A4/CYP2C9 inhibition occurs, in vivo drug-drug interaction risk is low but not absent.

Workflow Integration & Parameters

• Compound preparation: Dissolve anlotinib hydrochloride in DMSO to a stock concentration of 10 mM; store at -20°C.
• Capillary tube formation assay: Seed EA.hy 926 or HUVECs onto Matrigel; treat with 1–100 nM anlotinib; assess tube formation after 6–24 hours.
• Endothelial migration (wound healing): Pre-treat cells with 10–50 nM anlotinib for 1 hour before scratch; monitor migration over 12–24 hours.
• In vivo rat/mouse models: Administer orally at 1–10 mg/kg; monitor for anti-angiogenic endpoints and toxicity over 7–14 days.
• Pharmacokinetic sampling: Collect blood at 0.5, 1, 2, 4, 8, and 24 hours post-dose for LC-MS analysis.
• Negative controls: Include vehicle (DMSO) and comparator TKIs such as sunitinib or sorafenib at equimolar concentrations.

Conclusion & Outlook

Anlotinib hydrochloride, as provided by APExBIO, demonstrates highly selective, potent inhibition of key angiogenesis-driving kinases with minimal cytotoxicity, supporting its use in advanced cancer research protocols. Its superior benchmark performance and favorable pharmacokinetic properties make it a compelling tool for dissecting angiogenic pathways and validating therapeutic strategies. Ongoing translational studies will clarify its full potential and limitations in disease modeling (Gene, 2018).